Phio Pharmaceuticals (PHIO) AI Stock Analysis

• Market Cap: $11.18M
• Dividend Yield: N/A
• Average Volume (3M): 1.85M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.41
• Revenue Growth: N/A
• EPS Growth: 81.71%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -0.41
• Shares Outstanding: 4,798,154
• 10 Day Avg. Volume: 5,213,967
• 30 Day Avg. Volume: 1,849,820
• PEG Ratio: -0.42
• Price to Book (P/B): 9.24
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.16
• Enterprise Value/Market Cap: -0.10
• Enterprise Value/Revenue: -9.83
• Enterprise Value/Gross Profit: 0.16
• Enterprise Value/Ebitda: 0.03
• 1Y Price Target: $14.00
• Price Target Upside: 500.86% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 42 Neutral
• Price Target: ―

Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.

Positive Factors

Clinical Trials

PH-762 has already demonstrated impressive clinical activity and exhibited favorable safety in an early-stage Phase 1b trial.

Safety Profile

PH-762 administration was well-tolerated with no dose-limiting toxicities, serious adverse events, or clinically meaningful treatment-emergent adverse reactions reported.

Strategic Positioning

Phio maintains business development optionality as it advances its portfolio of conditionally active siRNA therapies, positioning itself well for potential partnerships.

Negative Factors

Clinical Trial Risks

The potential for the PH-762 Phase 1b study to generate data flow that could be positive catalysts through 2025 is underappreciated.

Funding Concerns

Factors that could impede reaching the price target include failed or inconclusive clinical trials and the inability to secure adequate funding.

Market Competition

Although the skin cancer therapy market is becoming increasingly crowded, a high unmet need persists due to the tumor's high incidence, less than optimal efficacy of available treatment options, and drug resistance to systemic therapies.

Phio Pharmaceuticals Business Overview & Revenue Model

Company Description

Phio Pharmaceuticals Corp. is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company specializes in the field of RNA interference (RNAi) and is pioneering the development of self-delivering RNAi (sd-rxRNA) therapeutics aimed at enhancing the efficacy of existing cancer treatments by targeting various pathways involved in tumor growth and immune evasion.

How the Company Makes Money

Phio Pharmaceuticals generates revenue through strategic partnerships, research collaborations, and licensing agreements related to its RNAi technology platform. The company aims to out-license its proprietary sd-rxRNA technology to larger pharmaceutical or biotechnology companies, which can incorporate these therapies into their own cancer treatment pipelines. Additionally, Phio may receive milestone payments and royalties from these partnerships based on the successful development and commercialization of its therapeutics. The company might also secure funding through grants and government programs aimed at supporting innovative cancer research.

Phio Pharmaceuticals Financial Statement Overview

Summary

Phio Pharmaceuticals is facing significant financial challenges with no revenue generation and ongoing operational losses. The balance sheet shows low leverage, but the cash flow situation is concerning due to consistent cash burn and a reliance on external financing. The company must focus on revenue generation and efficient cash management to improve its financial health.

Income Statement

Phio Pharmaceuticals has consistently reported zero revenue over the years, indicating a lack of product commercialization. The net income remains negative, reflecting persistent losses. The company's inability to generate revenue and its ongoing operational losses are significant concerns.

Balance Sheet

The company maintains a strong equity position relative to its assets, with a high equity ratio indicating minimal leverage. However, the substantial cash burn and diminishing cash reserves are potential risks if new funding is not secured.

Cash Flow

Operating cash flow remains negative, indicative of ongoing operational challenges. While the company has managed to secure financing to cover cash flow needs, the absence of free cash flow growth poses a risk to long-term sustainability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-6.33M	-193.00K	-192.00K	-183.00K
EBITDA	-7.12M	-10.64M	-11.29M	-13.09M	-8.72M
Net Income	-7.15M	-10.83M	-11.30M	-13.21M	-8.79M
Balance Sheet
Total Assets	5.74M	9.36M	12.81M	25.17M	15.74M
Cash, Cash Equivalents and Short-Term Investments	5.38M	8.49M	11.78M	24.06M	14.24M
Total Debt	0.00	35.00K	305.00K	295.00K	642.00K
Total Liabilities	1.01M	1.63M	1.98M	3.24M	2.72M
Stockholders Equity	4.72M	7.73M	10.84M	21.93M	13.02M
Cash Flow
Free Cash Flow	-7.11M	-10.75M	-12.25M	-11.91M	-8.82M
Operating Cash Flow	-7.11M	-10.75M	-12.13M	-11.86M	-8.80M
Investing Cash Flow	8.00K	-5.00K	-121.00K	-51.00K	-19.00K
Financing Cash Flow	4.00M	7.41M	-26.00K	21.72M	16.13M

Phio Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.33
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHIO, the sentiment is Neutral. The current price of 2.33 is below the 20-day moving average (MA) of 2.46, below the 50-day MA of 2.33, and above the 200-day MA of 2.20, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 45.87 is Neutral, neither overbought nor oversold. The STOCH value of 5.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PHIO.

Phio Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	50 Neutral	AU$2.63B	3.88	-56.57%	2.69%	36.37%	13.78%
PHIO	42 Neutral	$11.18M	―	-76.12%	―	―	81.71%
OTRK	37 Underperform	$2.17M	―	-215.66%	―	-21.03%	47.41%
GTBP	34 Underperform	$5.86M	―	-538.87%	―	―	-26.02%
AEON	24 Underperform	$8.22M	<0.01	13.29%	―	―	-261.69%
DRMA	15 Underperform	$3.97M	―	-206.26%	―	―	75.68%

Phio Pharmaceuticals Corporate Events

Phio Pharmaceuticals Appoints David Deming to Board

Phio Pharmaceuticals Corp. announced the appointment of David H. Deming to its Board of Directors, effective February 19, 2025. Mr. Deming, with over 30 years of experience in investment banking and asset management, will serve on the Board’s Nominating Committee. This strategic appointment is expected to bolster Phio’s capabilities as it advances its gene silencing technology in the biopharma sector, particularly in immuno-oncology therapeutics.